Aktiesnakken — August 2010
-
@moltved. Genmab er highrisk, men kan være interessant op til den 14. hvor de præsenterer deres nye strategi. OLGAC har jeg aldrig hørt om
-
metode, det var en joke. Jeg aner det ikke ;o)
-
Men vil ikke selv handle AMA før afklaring
-
Jeg tror intet, men forholder mig til hvad som sker
-
NO T-retter
-
Bl.a. pga. bankernes tossede system med at man skal købe T-retter senest 3 dage før sidste dag
Har set, at der er enormt mange anbefalinger til Genmab-aktien .. Størstedelen siger at man skal købe?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind